This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PBT2
Description: PBT2 is the first completely Prana-discovered compound, and is the successor to PBT1 for the treatment of Alzheimer's disease. PBT2 is designed to have an improved safety and efficacy profile compared to PBT1.
Both PBT-1 and PBT-2 work by binding metal ions. The metal theory of Alzheimer's disease is based on the premise that key metals, such as zinc and copper, are required for the inappropriate aggregation of amyloid beta to form the amyloid plaques. These plaques are then thought to cause the neurodegeneration associated with Alzheimer's disease. The metal-mediated aggregation of proteins is also thought to be a key contributor to the development of a variety of other degenerative disorders.
PBT2 has demonstrated greater effectiveness than PBT1 in lowering plaque in the transgenic mouse model in both pre-clinical in-vitro and in-vivo testing. Moreover, it appears to be better than PBT1 at decreasing the toxicity of plaques through improved peroxide inhibition, and appears to have better pharmaceutical characteristics, such as improved solubility.
Additional information available to subscribers only: